Rekovelle 12 micrograms/0,36 ml & 36 micrograms/1,08 ml & 72 micrograms/2,16 ml Solution for injection..
Clinical Summary
Quick overview from the medicine insert
Indication
Controlled ovarian stimulation in women undergoing ART.
Dosage (summary)
Individualized based on AMH and body weight; max 24 micrograms.
Onset of Action / Duration
Onset: 5-20 days for follicular development.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Contraindications
- Hypersensitivity to active substance
- Tumours of hypothalamus or pituitary gland
- Ovarian enlargement or cysts not due to PCOS
- Gynaecological haemorrhages of unknown aetiology
- Ovarian, uterine or mammary carcinoma
- Pregnancy and lactation
- Not for use in males
Common side effects
- Headache
- Pelvic discomfort
- Ovarian hyperstimulation syndrome (OHSS)
- Pelvic pain
- Nausea
- Fatigue
Counselling Points
- Monitor for OHSS symptoms.
- Educate on injection technique.
- Discuss risks of multiple pregnancies.
- Avoid pregnancy during treatment.
Serious warnings
- Risk of OHSS
- Thromboembolic events
- Ovarian torsion
- Multiple pregnancy risk
- Pregnancy loss risk
- Ectopic pregnancy risk
The Rekovelle 12 micrograms/0,36 ml & 36 micrograms/1,08 ml & 72 micrograms/2,16 ml Solution for injection.. professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.